Type 1 Diabetes Clinical Trial
Official title:
Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes
Verified date | March 2024 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Adolescence presents a challenging time for type 1 diabetes management, and despite a multitude of studies aimed at increasing disease compliance in this age group, none have been deemed superior. The purpose of this study is to incorporate mindfulness skills in with diabetes education sessions for adolescents with type 1 diabetes and study if this translates to improved outcomes in glycemic control, patient satisfaction, and mental wellness.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | July 7, 2024 |
Est. primary completion date | March 5, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 17 Years |
Eligibility | Inclusion Criteria: - Age 15-17 years - Diagnosis of type 1 diabetes for at least 12 months - Uncontrolled diabetes with A1c at least 9.0% - Parent or guardian agrees for adolescent to participate Exclusion Criteria: - Diagnosed cognitive disabilities - Other uncontrolled chronic diseases as assessed by PI - Inability to attend visits due to individual schedules |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University Health Methodist Hospital | Indianapolis | Indiana |
United States | Riley Hospital for Children | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | Eli Lilly and Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient Health Questionnaire for Adolescents (PHQ-A) | Measure of general health and wellbeing. The change in the PHQ-A will be measured from baseline to 12 months. | 12 months | |
Other | Screen for Childhood Anxiety Related Emotional Disorders (SCARED-5) questionnaire | The change in the SCARED-5 will be measured from baseline to 12 months. | 12 months | |
Other | Problem Areas in Diabetes - Teens (PAID-T) questionnaire | The change in the PAID-T will be measured from baseline to 12 months. | 12 months | |
Other | Peds QL Diabetes Module questionnaire | The change in the Peds QL Diabetes Module will be measured from baseline to 12 months. | 12 months | |
Other | Mindful Attention Awareness Scale (MAAS) questionnaire for adolescents | The change in the MAAS will be measured from baseline to 12 months. | 12 months | |
Other | Difficulties in Emotion Regulation Scale (DERS) questionnaire | The change in the DERS will be measured from baseline to 12 months. | 12 months | |
Other | Child and Adolescent Social Support Scale (CASSS) questionnaire | The change in the parent and friends subscales of the CASSS will be measured from baseline to 12 months. | 12 months | |
Primary | Feasibility of intervention in the study population. | Feasibility of recruitment, retention of participants, and intervention completion. This will be measured by considering study participation rate, time to recruit, attendance, study retention rate, study completion rate, participant burden, and data completeness. | 12 months | |
Primary | Acceptability of intervention in the study population. | This will be measured by participant satisfaction surveys. | 12 months | |
Secondary | Hemoglobin A1c (HbA1c, %) | The change in HbA1c will be measured from baseline to 12 months. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |